Clinical Study
An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients
Table 5
Comparisons between patients with and without BKV replication within bone marrow.
| | | Patients with BKV replication in bone marrow: | Patients without BKV replication in bone marrow: | value |
| | Male gender (%) | 6 (75%) | 34 (53%) | ns | | Age (years) | | | ns | | Serum creatinine (µmol/L) | | | 0.05 | | DFG (mL/min) | | | 0.04 | | Retransplantation (%) | 1 (12.5%) | 12 (19%) | ns |
| | Immunosuppressive therapy | | RATG (%) | 5 (62.5%) | 24 (37.5%) | ns | | Rituximab (%) | 2 (25%) | 11 (17%) | ns | | Steroid pulses (%) | 4 (50%) | 20 (31%) | ns | | Plasma exchange (%) | 2 (25%) | 13 (20%) | ns | | CNIs at bone-marrow analysis (%) | 6 (75%) | 57 (89%) | ns | | MPA at bone-marrow analysis (%) | 7 (87.5%) | 53 (83%) | ns | | MPA dose at bone-marrow analysis (mg/kg/d) | | | ns | | Steroid-sensitive acute-rejection episodes (%) | 3 (5%) | 10 (15.6%) | ns | | Steroid-resistant acute-rejection episodes (%) | 1 (12.5%) | 8 (12.5%) | ns | | Antibody-mediated rejection episodes (%) | 2 (25%) | 8 (12.5%) | ns | | Hemoglobin level at bone-marrow analysis (g/dL) | | | 0.06 | | PMN counts at bone-marrow analysis (/mm³) | 695 (50–990) | 944 (20–8821) | ns | | Platelet counts at bone-marrow analysis (/mm³) | 147,375 ± 67,692 | 156,593 ± 102,028 | ns | | Lymphocyte counts (/mm³) | 600 (155–730) | 464 (27–3656) | ns | | CD4-positive cell counts (/mm³) | 294 (34–884) | 183 (31–2012) | ns | | CD8-positive cell counts (/mm³) | 223 (27–790) | 161 (12–1293) | ns | | CD19-positive cell counts (/mm³) | 51 (0–918) | 35 (0–239) | ns | | Gamma globulin levels (g/L) | 5.7 (4.5–7.8) | 6.9 (2.7–14) | ns | | BK viremia at bone-marrow analysis (%) | 5 (62.5%) | 4 (6.25%) | 0.0004 | | Cytomegalovirus viremia (%) | 0 (0%) | 9 (14%) | ns |
|
|
RATG: rabbit anti-thymocyte globulins; CNIs: calcineurin inhibitors; MPA: mycophenolic acid; PMN: polymorphonuclear leukocytes.
|
